Modular Medical, Inc. (MODD) just cleared a major hurdle on its path to market. On Thursday, the company announced that the U.S. Food & Drug Administration (FDA) has signed off on a batch of software enhancements for its Pivot insulin delivery system.
These upgrades aren't just cosmetic. They expand what the system can do, giving users more flexibility and customization when it comes to bolus dosing, along with a refreshed user interface and other software tweaks. Think of it as a firmware update that makes the device more personal.
The company had submitted these enhancements to the FDA back in July, so the timing of this clearance is notable. It lands right before the planned fourth-quarter launch, which is exactly what CEO Jeb Besser was hoping for.
"We are pleased that this clearance was received in advance of our planned fourth quarter launch. The cleared improvements represent the first in a series of enhancements and upgrades to the Pivot platform and were designed to expand the functionality and flexibility of Pivot for users, including the ability to customize the amount of insulin delivered with each button push," Besser said.
That last bit is key: users will be able to dial in exactly how much insulin each button press delivers. It's a small but meaningful feature for people who need precise control.
This news follows the company's August announcement that it would start the first phase of commercialization for the Pivot tubeless patch pump across five carefully chosen U.S. markets, beginning in October 2026. To help with that rollout, Modular Medical has teamed up with Inizio, a global commercialization partner.
Investors seem to like what they're seeing. Modular Medical shares were up 6.94% at $3.70 during premarket trading Thursday.
With FDA clearance in hand and a launch date on the horizon, Modular Medical is moving from development mode to execution mode. The next few months will show whether the Pivot pump can carve out its place in the competitive insulin delivery market.
